Condition: Prostate Cancer (Adenocarcinoma) · mCRPC (Metastatic Castration-resistant Prostate Cancer) · Sponsor: Prostate Cancer Clinical Trials Consortium
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate.
This description comes directly from the study's public registry record.
Sarah Wise · 215-380-9051 · wises@mskcc.org
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Masonic Cancer Center | Minneapolis, Minnesota, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Abramson Cancer Center of the University of Pennsylvania, Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
| University of Wisconsin Carbone Cancer Center-Madison | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06844383